Cargando…

Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer

Anaplastic (ATC) and refractory papillary thyroid cancer (PTC) lack effective treatments. Inhibition of either oncogenic BRAF or SRC has marked anti-tumor effects in mouse models of thyroid cancer, however, neither drug induces notable apoptosis. Here we report that the SRC-inhibitor dasatinib furth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Borre, Pierre Vanden, Gunda, Viswanath, McFadden, David G., Sadow, Peter M., Varmeh, Shohreh, Bernasconi, Maria, Parangi, Sareh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Priority Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147301/ https://www.ncbi.nlm.nih.gov/pubmed/24994118

Ejemplares similares

Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer
por: Brauner, Eran, et al.
Publicado: (2016)

Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer
por: Gunda, Viswanath, et al.
Publicado: (2018)

The BRAF(V600E) mutation: what is it really orchestrating in thyroid cancer?
por: Nucera, Carmelo, et al.
Publicado: (2010)

Targeting BRAF(V600E) with PLX4720 Displays Potent Antimigratory and Anti-invasive Activity in Preclinical Models of Human Thyroid Cancer
por: Nucera, Carmelo, et al.
Publicado: (2011)

Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAF(V600E) patient-derived papillary thyroid carcinoma preclinical model
por: Duquette, Mark, et al.
Publicado: (2015)

BRAF activating mutations involving the β3-αC loop in V600E-negative anaplastic pleomorphic xanthoastrocytoma
por: Pratt, Drew, et al.
Publicado: (2018)

mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition
por: Xue, Gongda, et al.
Publicado: (2017)

Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways
por: Gunda, V, et al.
Publicado: (2014)

Modeling the tumor microenvironment of anaplastic thyroid cancer: an orthotopic tumor model in C57BL/6 mice
por: Xu, Zhen, et al.
Publicado: (2023)

ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs)
por: Prasetyanti, Pramudita R., et al.
Publicado: (2015)

Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAF(V600E)
por: Antonello, Zeus A., et al.
Publicado: (2017)

Thrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells with BRAF(V600E): New Insights in the Host Tissue Adaptation and Homeostasis of Tumor Microenvironment
por: Duquette, Mark, et al.
Publicado: (2013)

Corrigendum: Thrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells With BRAF(V600E): New Insights in the Host Tissue Adaptation and Homeostasis of Tumor Microenvironment
por: Duquette, Mark, et al.
Publicado: (2020)

BRAF(V600E) mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas
por: Takano, T, et al.
Publicado: (2007)

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
por: Lang, Matthias, et al.
Publicado: (2023)

Genetic landscape of extreme responders with anaplastic oligodendroglioma
por: Holdhoff, Matthias, et al.
Publicado: (2017)

A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF(V600E) colorectal tumors
por: Ruiz-Saenz, Ana, et al.
Publicado: (2023)

Prognostic relevance of miRNA-155 methylation in anaplastic glioma
por: Schliesser, Maximilian Georg, et al.
Publicado: (2016)

Clostridium novyi-NT can cause regression of orthotopically implanted glioblastomas in rats
por: Staedtke, Verena, et al.
Publicado: (2015)

Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma
por: Iyer, Priyanka C., et al.
Publicado: (2018)

Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition
por: Wilson, Catherine, et al.
Publicado: (2014)

SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer
por: Gururajan, Murali, et al.
Publicado: (2015)

Immunocompetent mouse allograft models for development of therapies to target breast cancer metastasis
por: Yang, Yuan, et al.
Publicado: (2017)

LGG-08. MR Imaging of pediatric low-grade gliomas: Pretherapeutic differentiation ofBRAF V600E mutation,BRAF-Fused and Wild-Type tumors in patients without Neurofibromatosis-1
por: Trasolini, Andrew, et al.
Publicado: (2022)

Comparison of SARS-CoV-2 RT-PCR on a high-throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the diagnostic of COVID-19 on various clinical samples
por: Opota, Onya, et al.
Publicado: (2020)

LINC00520 is induced by Src, STAT3, and PI3K and plays a functional role in breast cancer
por: Henry, Whitney S., et al.
Publicado: (2016)

Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells
por: Spender, Lindsay C., et al.
Publicado: (2016)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
por: Sewell, Will, et al.
Publicado: (2013)

BRAF V600E and SRC mutations as molecular markers for predicting prognosis and conversion surgery in Stage IV colorectal cancer
por: Shimada, Yoshifumi, et al.
Publicado: (2019)

Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAF(V600E)-Mutated Anaplastic Thyroid Carcinoma
por: Wang, Jennifer R., et al.
Publicado: (2019)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Regulation of E-cadherin localization by microtubule targeting agents: rapid promotion of cortical E-cadherin through p130Cas/Src inhibition by eribulin
por: Dybdal-Hargreaves, Nicholas F., et al.
Publicado: (2017)

Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAF(V600E) Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study
por: Zhao, Xiao, et al.
Publicado: (2023)

Genetics, Diagnosis, and Management of Hürthle Cell Thyroid Neoplasms
por: McFadden, David G., et al.
Publicado: (2021)

BRAF V600E protect from cell death via inhibition of the mitochondrial permeability transition in papillary and anaplastic thyroid cancers
por: Gao, Yanyan, et al.
Publicado: (2022)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways
por: Jain, Payal, et al.
Publicado: (2017)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

Complete response of metastatic BRAF V600-mutant anaplastic thyroid cancer following adjuvant dabrafenib and trametinib treatment: A case report
por: Lee, Sang Jae, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4eu3vdfdb7bta8qj5qrh2vkfbg